KYNTRA BIO, INC.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
KYNB$3.90+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(47,579) | $(284,232) |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 1,166 | (3,712) |
| Available-for-sale investments: | ||
| Unrealized gain (loss) on investments, net of tax effect | (23) | 2,557 |
| Other comprehensive gain (loss), net of taxes | 1,143 | (1,155) |
| Comprehensive loss | (46,436) | (285,387) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.